Multi-target research partnership for drug discovery in oncology and painAssembly of novel high-diversity small molecule library Library collection distinguished by novel unique design concepts based...
Orion Group Financial Statement documents 2022, Corporate Governance Statement and Remuneration Report published
Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in China
Orion and Bayer’s Phase III ARASENS trial has demonstrated an increase nin overall survival, evaluating darolutamide in combination with ndocetaxel and androgen deprivation therapy (ADT), compared to docetaxel nand ADT, a standard of care in metastatic hormone-sensitive prostate ncancer (mHSPC). Bayer aims to present these ground-breaking data at a nforthcoming scientific congress, and will discuss them with health nauthorities.